Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mary Rose, Pambid"'
Autor:
Sandra E. Dunn, Christopher Dunham, Sheila K. Singh, Paul Northcott, Stephen Yip, Rod Rassekh, Juliette Hukin, Ash Singhal, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Cynthia Hawkins, Aru Narendran, Katrina O'Halloran, Chitra Venugopal, Abbas Fotovati, Rachel Berns, Mary Rose Pambid, Branavan Manoranjan, Colleen Foster, Cathy Lee, Joanna Triscott
Medulloblastoma is the most common malignant brain tumor in children. This disease is heterogeneous and is composed of four subtypes of medulloblastoma [WNT, Sonic Hedgehog (SHH), Group 3, and Group 4]. An immediate goal is to identify novel molecula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2676c0f11180d32a7b8ade9835657025
https://doi.org/10.1158/0008-5472.c.6505601
https://doi.org/10.1158/0008-5472.c.6505601
Autor:
Sandra E. Dunn, Christopher Dunham, Sheila K. Singh, Paul Northcott, Stephen Yip, Rod Rassekh, Juliette Hukin, Ash Singhal, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Cynthia Hawkins, Aru Narendran, Katrina O'Halloran, Chitra Venugopal, Abbas Fotovati, Rachel Berns, Mary Rose Pambid, Branavan Manoranjan, Colleen Foster, Cathy Lee, Joanna Triscott
PDF file - 80K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1105923776f2fa6159acbf1c2f1d4367
https://doi.org/10.1158/0008-5472.22400492.v1
https://doi.org/10.1158/0008-5472.22400492.v1
Autor:
Sandra E. Dunn, Christopher Dunham, Sheila K. Singh, Paul Northcott, Stephen Yip, Rod Rassekh, Juliette Hukin, Ash Singhal, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Cynthia Hawkins, Aru Narendran, Katrina O'Halloran, Chitra Venugopal, Abbas Fotovati, Rachel Berns, Mary Rose Pambid, Branavan Manoranjan, Colleen Foster, Cathy Lee, Joanna Triscott
PDF file - 685K, Supplementary Table S1. Summary of the pediatric MB patients included in the study Discovery cohort. Supplementary Table S2. Summary of the pediatric MB patients included in the study Validation cohort. Supplementary Table S3. PAM cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a19d6b4ff4989b69f799a74f683b628
https://doi.org/10.1158/0008-5472.22400489
https://doi.org/10.1158/0008-5472.22400489
Autor:
Muralidhar Beeram, Judy S. Wang, Lida A. Mina, Pavani Chalasani, Rebecca A. Shatsky, Robert Wesolowski, Sara A. Hurvitz, Meghna S. Trivedi, Hyo S. Han, Amita Patnaik, My-my Huynh, Aarthi Jayanthan, Mary Rose Pambid, Lambert Yue, Gerrit Los, Sandra E. Dunn, Andrew Dorr
Publikováno v:
Cancer Research. 82:P5-17
Background: Durably effective therapeutic options remain elusive for metastatic triple negative breast cancer (mTNBC) patients. RSK is a novel target kinase for mTNBC, given its integral role in the MAPK/PDK-1 pathways. PMD-026, uniquely developed fo
Autor:
Lida A. Mina, F. Andrew Dorr, My-my Huynh, Gerrit Los, Judy S. Wang, Pavani Chalasani, Aarthi Jayanthan, Murali Beeram, Amita Patnaik, Sandra E. Dunn, Mary Rose Pambid
Publikováno v:
Cancer Research. 81:PS11-33
Background: Metastatic breast cancer (mBC) remains an aggressive disease with limited durable treatment options; the worst prognosis among the breast cancer subtypes is typically seen in metastatic triple-negative breast cancer (mTNBC). Given that un
Publikováno v:
Expert Opinion on Investigational Drugs. 29:1199-1208
Triple negative breast cancer (TNBC) was once thought to be an insurmountable disease marked by a lack of targeted treatments. However, we are now witnessing the dawn of targeted therapies for TNBC in which progress has stemmed from an improved under
Publikováno v:
Expert opinion on therapeutic targets. 24(1)
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characteristically associated with worse outcomes compared to other breast cancer subtypes. Cytotoxic chemother...
Autor:
Aarthi Jayanthan, Jangsoon Lee, Mary Rose Pambid, Naoto T. Ueno, Sandra E. Dunn, Gerrit Los, Lambert Yue, My-my Huynh
Publikováno v:
Cancer Research. 81:1038-1038
PMD-026 is a first in class, reversible, oral small molecule inhibitor of p90 ribosomal S6 kinase (RSK), a kinase family activated by the MAPK and PDK-1 pathways, which regulate substrates involved in cancer cell proliferation and drug resistance. Sp
Autor:
Judy Sing-Zan Wang, Andrew Dorr, Muralidhar Beeram, Rebecca Shatsky, Hyo S. Han, Gerrit Los, Robert Wesolowski, Meghna S. Trivedi, Sandra E. Dunn, Pavani Chalasani, My-my Huynh, Amita Patnaik, Lida Mina, Sara A. Hurvitz, Aarthi Jayanthan, Mary Rose Pambid
Publikováno v:
Journal of Clinical Oncology. 39:e13043-e13043
e13043 Background: P90 ribosomal S6 kinase (RSK) is an actionable molecular target against metastatic triple negative breast cancer (mTNBC). RSK is a major convergence point in the integral TNBC signaling pathways, MAPK and PDK-1. PMD-026 is a first-
Autor:
Mary Rose Pambid, Amita Patnaik, Judy S. Wang, Gerrit Los, Muralidhar Beeram, Andrew Dorr, Lida A. Mina, My-my Huynh, Sandra E. Dunn, Aarthi Jayanthan
Publikováno v:
Journal of Clinical Oncology. 38:TPS1110-TPS1110
TPS1110 Background: Metastatic triple negative breast cancer (mTNBC) has a poor prognosis with limited durable treatment options. RSK (P90 ribosomal S6 kinase) is a signaling protein at the convergence point of PDK-1 and MAPK signaling pathways. RSK1